| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:532-536.)
© 2004 American Heart Association, Inc.
Basic Science Reports |
From the Institute of Cardiology (L.P., F.G., G.M., L.T., F.C., C.M, A.B.) and the Institute of Experimental Medicine, Section of Microbiology (G.F., T.L., L.G., M.P.L.), University of Bologna, Bologna, Italy; and the Department of Virology, Institute of Microbiology, Albert Einstein University, Ulm, Germany (G.F.).
Correspondence to Carlo Magelli, MD, Institute of Cardiology, Pad. 21, Via Massarenti 9, 40138 Bologna, Italy. E-mail bibcard{at}almadns.unibo.it; lpotena@cvmed.stanford.edu
Received March 4, 2003; de novo received July 31, 2003; revision received October 2, 2003; accepted October 6, 2003.
Background Statins exert anti-inflammatory effects independently of cholesterol-lowering properties. Cytomegalovirus (CMV) infection appears to be implicated in the pathophysiology of atherosclerosis by inducing inflammatory modifications in endothelial cells, especially in immunosuppressed patients. We investigated whether the activity of statins can inhibit replication of CMV in human endothelial cells.
Methods and Results Human umbilical vein endothelial cells (HUVECs) were infected with CMV and coincubated with fluvastatin at 0.1 and 0.2 µmol/L. Fluvastatin inhibited (P<0.001) CMV antigen expression, and this effect was dose related (P<0.001). Quantitative polymerase chain reaction showed that CMV DNA concentration was consistently lower in supernatants from fluvastatin-treated cells than in infected controls, and viral particle concentration was up to 30 times lower in 0.2 µmol/L fluvastatin-treated cells than in infected controls (10.5±0.9 versus 0.34±0.03 per 103 pfu/mL, P<0.001). Addition of mevalonate to treated cultures almost completely abolished fluvastatin inhibition of viral growth. Electrophoretic mobility shift assay showed that fluvastatin reduced nuclear factor-
B binding activity in CMV-infected cells.
Conclusions HMG-CoA inhibition by fluvastatin restrains CMV replication in HUVECs by inhibiting viral antigen expression, DNA synthesis, and viral particle production, conceivably by involving a reduction of nuclear factor-
B binding activity.
Key Words: statins atherosclerosis endothelium infection viruses
This article has been cited by other articles:
![]() |
I. M. Tleyjeh, T. Kashour, F. A. Hakim, V. A. Zimmerman, P. J. Erwin, A. J. Sutton, and T. Ibrahim Statins for the Prevention and Treatment of Infections: A Systematic Review and Meta-analysis Arch Intern Med, October 12, 2009; 169(18): 1658 - 1667. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Erkkila, M. Jauhiainen, K. Laitinen, K. Haasio, T. Tiirola, P. Saikku, and M. Leinonen Effect of Simvastatin, an Established Lipid-Lowering Drug, on Pulmonary Chlamydia pneumoniae Infection in Mice Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3959 - 3962. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |